Percentage of patients, aged 50-years-old or older, who have had a screening ultrasound for an abdominal aortic aneurysm (AAA), with positive or negative findings, that have recognized clinical follow-up recommendations documented in the final report and direct communication of findings greater than or equal to 5.5 cm in size made to the ordering provider.
Measure Type: High Priority
Appropriate Classification and Follow-up Imaging for Incidental Pancreatic Cysts
Percentage of final reports for computed tomography/computed tomography angiography (CT/CTA) of the abdomen or abdomen/pelvis or magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) of the abdomen for patients 18 years of age and older with a pancreatic cyst incidentally noted that include documentation of cyst classification/morphology and follow-up imaging recommendation(s) in accordance with published guidelines and source of recommendation.
Oncology: Patient-Reported Pain Improvement
Percentage of cancer patients currently receiving chemotherapy or radiation therapy who report significant pain improvement (high to moderate, moderate to low, or high to low) within 30 days.
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life
Percentage of patients receiving supportive care drugs (including colony stimulating factors, bone health, supplemental iron medications, and neurokinin 1 (NK1) receptor antagonist antiemetics) during the 14 days prior to and including the date of death.
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
Percentage of patients tested for Hepatitis B prior to receiving anti-CD20 targeting treatment, including rituximab, ofatumumab, and obinutuzumab; patients testing positive for Hepatitis B receive prophylactic treatment.
Oncology: Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
Proportion of stage IV nsNSCLC patients tested for actionable biomarkers and received targeted therapy or chemotherapy based on biomarker results
Oncology: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (inverse measure)
Percentage of patients with cancer (solid tumors only) receiving any white cell growth factors with during the first cycle of low-risk chemotherapy.
Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)
Percentage of cancer patients aged 18 years and older treated with low- or minimal-emetic-risk antineoplastic agents who are administered inappropriate pre-treatment antiemetic therapy
Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents
Percentage of cancer patients aged 18 years and older treated with high- or moderate-emetic-risk antineoplastic agents who are administered appropriate pre-treatment antiemetic therapy
Oncology: Screening and Achieving Resolution or Improvement of Distress for Cancer Care
Percentage of patients 18 years and older with an active cancer diagnosis who are screened for distress AND if screen is positive, achieve resolution or improvement within 6 months for at least 1 of their concerns.
THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE:
1) Patients 18 years and older with an active cancer diagnosis who are screened for distress using a comprehensive, standardized tool which assesses physical, emotional, social, practical, and spiritual concerns.
AND
2) Patients 18 years and older with an active cancer diagnosis who screen positive for distress using a comprehensive, standardized screening tool and achieve resolution or improvement within 6 months for at least 1 of their concerns.
The measure contains two submission criteria which aim to identify patients who were screened for distress (Submission Criteria 1) and of those patients who screened positive for distress, did corresponding interventions following a positive distress screening lead to meaningful improvement or resolution within 6 months (Submission Criteria 2). By separating this measure into various submission criteria, the MIPS eligible clinician or practice will be able to better ascertain where gaps in performance exist and identify opportunities for improvement. For accountability reporting in the CMS MIPS program, the rate for Submission Criteria 2 is used for performance.